CGENHealthcare · BiotechnologyThe 5 Wall Street analysts covering Compugen Ltd. hold a median 12-month price target of $4 — +52.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Compugen Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CGEN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +52.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 May 2026 | Leerink Partners | Maintains | Outperform | $13 → $5.00 |
| 7 Apr 2026 | Lake Street | Initiates | Buy | — |
| 7 Jan 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 21 May 2024 | Truist Securities | Maintains | Buy | — |
| 8 Mar 2024 | Truist Securities | Maintains | Buy | — |
| 19 Dec 2023 | Stifel | Maintains | Buy | — |
| 23 Aug 2023 | Truist Securities | Reiterates | Buy | — |
| 7 Aug 2023 | EF Hutton | Reiterates | Buy | — |
| 6 June 2023 | EF Hutton | Reiterates | Buy | — |
| 26 May 2023 | EF Hutton | Reiterates | Buy | — |
| 24 May 2023 | EF Hutton | Reiterates | Buy | — |
| 16 May 2023 | Oppenheimer | Maintains | Outperform | — |
| 28 Feb 2023 | Oppenheimer | Reiterates | Outperform | — |
| 8 Feb 2023 | Jefferies | Downgrade | Underperform | — |
| 5 Jan 2023 | EF Hutton | Initiates | Buy | — |
| 15 Nov 2022 | Oppenheimer | Maintains | Outperform | — |
| 23 Aug 2022 | Truist Securities | Maintains | Buy | — |
| 8 Aug 2022 | JMP Securities | Maintains | Market Outperform | — |
| 8 Aug 2022 | Oppenheimer | Maintains | Outperform | — |
| 5 Aug 2022 | Jefferies | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEN appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 64% of US stocks
Cheaper than 38% of US stocks
Cheaper than 37% of US stocks
Cheaper than 54% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 96% of US stocks
Higher than 93% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Compugen Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
This Zacks Investment Research piece compares how Compugen (CGEN) and Envoy Medical (COCH) have performed relative to their sector so far this year. It provides a year-to-date performance review of the two medical stocks against their group.
Why it matters — CGEN watchers would want to see how the company's stock performance compares with its sector peers so far this year.
The article notes that Compugen has improved its cash runway to support operations into 2029, which should carry the company through the interim analysis of the MAIA trial. It identifies MAIA as the main value driver and suggests that a positive randomized readout could help validate COM701 and the broader PVRIG approach.
Why it matters — A longer runway reduces near-term financing risk and better positions CGEN to reach its key MAIA clinical data milestone.
Seeking Alpha published the transcript of Compugen Ltd.'s (CGEN) Q2 2026 earnings call. The item is a transcript of the company's second-quarter 2026 earnings call.
Why it matters — A CGEN watcher would care because earnings-call transcripts provide management's commentary on quarterly results and company outlook.
Compugen reported that its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancement of partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.
Why it matters — A CGEN watcher would care because the update signals ongoing clinical progress, strong partnership execution, and financial stability extending into 2029.
Compugen reported a Q2 loss of $0.07 per share, matching the Zacks Consensus Estimate and narrowing from a loss of $0.08 per share in the same quarter last year. The company's results missed revenue estimates.
Why it matters — The quarterly results provide the latest snapshot of Compugen's financial performance, including whether the company is making progress toward narrowing its losses.
The 5 Wall Street analysts covering Compugen Ltd. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Compugen Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compugen Ltd. 82 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Compugen Ltd. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +52.7% from the last close, and Ticker Nerd's factor model ranks Compugen Ltd. 82 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Compugen Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
Compugen Ltd. returned +83.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML.
The most recent item we track (Zacks Investment Research, 21 Aug 2026): "Are Medical Stocks Lagging Compugen (CGEN) This Year?". This Zacks Investment Research piece compares how Compugen (CGEN) and Envoy Medical (COCH) have performed relative to their sector so far this year. It provides a year-to-date performance review of the two medical stocks against their group.
Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML. It utilizes its proprietary Unigen™ platform, a predictive AI/ML-powered computational discovery tool, to identify novel drug targets and biological pathways for developing immuno-oncology therapies. The company advances wholly owned clinical programs such as COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody in Phase 1 for platinum-resistant ovarian cancer and maintenance therapy in relapsed cases, and COM902, an Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 for solid tumors. Compugen also maintains partnered programs, including bispecific antibodies with AstraZeneca featuring the TIGIT component from COM902, and GS-0321 (formerly COM503), a high-affinity anti-IL-18 binding protein antibody licensed to Gilead for Phase 1 development in advanced solid malignancies. Its pipeline extends to early-stage immuno-oncology research programs targeting new mechanisms to activate the immune system against cancer and overcome resistance. Founded in Israel and headquartered there with offices in San Francisco, California, Compugen Ltd. plays a key role in advancing differentiated antibody therapies in the oncology sector.
CEO Dr. Eran Ophir Ph.D. · 75 employees · Israel · https://cgen.com